JP2003535859A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003535859A5 JP2003535859A5 JP2002501890A JP2002501890A JP2003535859A5 JP 2003535859 A5 JP2003535859 A5 JP 2003535859A5 JP 2002501890 A JP2002501890 A JP 2002501890A JP 2002501890 A JP2002501890 A JP 2002501890A JP 2003535859 A5 JP2003535859 A5 JP 2003535859A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- group
- formula
- pyrrolidin
- amino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 cyano, isocyano, nitro, hydroxy, mercapto, amino, formyl Chemical group 0.000 claims description 653
- 125000000217 alkyl group Chemical group 0.000 claims description 350
- 125000001424 substituent group Chemical group 0.000 claims description 146
- 125000000623 heterocyclic group Chemical group 0.000 claims description 89
- 229910052739 hydrogen Inorganic materials 0.000 claims description 76
- 239000001257 hydrogen Substances 0.000 claims description 76
- 229910052760 oxygen Inorganic materials 0.000 claims description 75
- 229910052757 nitrogen Inorganic materials 0.000 claims description 67
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 60
- 125000003545 alkoxy group Chemical group 0.000 claims description 49
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 47
- 125000003118 aryl group Chemical group 0.000 claims description 42
- 125000001072 heteroaryl group Chemical group 0.000 claims description 39
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 39
- 125000001153 fluoro group Chemical group F* 0.000 claims description 37
- 125000005843 halogen group Chemical group 0.000 claims description 35
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 34
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 30
- 229910052717 sulfur Inorganic materials 0.000 claims description 25
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 24
- 125000005236 alkanoylamino group Chemical group 0.000 claims description 22
- 125000004432 carbon atom Chemical group C* 0.000 claims description 22
- 125000005115 alkyl carbamoyl group Chemical group 0.000 claims description 20
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 20
- 125000002947 alkylene group Chemical group 0.000 claims description 19
- 238000003780 insertion Methods 0.000 claims description 19
- 230000037431 insertion Effects 0.000 claims description 19
- 125000003282 alkyl amino group Chemical group 0.000 claims description 18
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 16
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims description 16
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 claims description 16
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 14
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 14
- 229910052799 carbon Inorganic materials 0.000 claims description 14
- 125000003342 alkenyl group Chemical group 0.000 claims description 13
- 125000000304 alkynyl group Chemical group 0.000 claims description 13
- 229910002091 carbon monoxide Inorganic materials 0.000 claims description 13
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 13
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 11
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 claims description 9
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 9
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims description 9
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 claims description 8
- 229920002554 vinyl polymer Polymers 0.000 claims description 8
- 125000003302 alkenyloxy group Chemical group 0.000 claims description 7
- 125000005133 alkynyloxy group Chemical group 0.000 claims description 7
- 150000003839 salts Chemical class 0.000 claims 28
- 150000003246 quinazolines Chemical class 0.000 claims 25
- 150000002431 hydrogen Chemical class 0.000 claims 15
- 239000002253 acid Substances 0.000 claims 12
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 12
- 150000001875 compounds Chemical class 0.000 claims 12
- 125000001589 carboacyl group Chemical group 0.000 claims 11
- 125000005153 alkyl sulfamoyl group Chemical group 0.000 claims 10
- 125000004644 alkyl sulfinyl group Chemical group 0.000 claims 10
- 125000004414 alkyl thio group Chemical group 0.000 claims 10
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims 10
- 125000001246 bromo group Chemical group Br* 0.000 claims 10
- 125000004423 acyloxy group Chemical group 0.000 claims 9
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims 9
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 8
- 125000000524 functional group Chemical group 0.000 claims 8
- 125000004043 oxo group Chemical group O=* 0.000 claims 8
- 125000000555 isopropenyl group Chemical group [H]\C([H])=C(\*)C([H])([H])[H] 0.000 claims 6
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims 5
- LCIYFINKFGDAHD-UHFFFAOYSA-N azepane;3-nitrobenzoic acid Chemical compound C1CCCNCC1.OC(=O)C1=CC=CC([N+]([O-])=O)=C1 LCIYFINKFGDAHD-UHFFFAOYSA-N 0.000 claims 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 5
- 238000006243 chemical reaction Methods 0.000 claims 4
- 125000006239 protecting group Chemical group 0.000 claims 4
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 claims 4
- 125000002619 bicyclic group Chemical group 0.000 claims 3
- 125000002618 bicyclic heterocycle group Chemical group 0.000 claims 3
- 125000000467 secondary amino group Chemical group [H]N([*:1])[*:2] 0.000 claims 3
- 125000000464 thioxo group Chemical group S=* 0.000 claims 3
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 claims 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 2
- 150000001412 amines Chemical class 0.000 claims 2
- 238000003776 cleavage reaction Methods 0.000 claims 2
- 230000008878 coupling Effects 0.000 claims 2
- 238000010168 coupling process Methods 0.000 claims 2
- 238000005859 coupling reaction Methods 0.000 claims 2
- 125000002933 cyclohexyloxy group Chemical group C1(CCCCC1)O* 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- QPKZNXSXCNZSDC-UHFFFAOYSA-N n-(5-chloro-1,3-benzodioxol-4-yl)-5-(oxan-4-yloxy)-7-(2-pyrrolidin-1-ylethoxy)quinazolin-4-amine Chemical compound ClC1=CC=C2OCOC2=C1NC(C1=C(OC2CCOCC2)C=2)=NC=NC1=CC=2OCCN1CCCC1 QPKZNXSXCNZSDC-UHFFFAOYSA-N 0.000 claims 2
- HLILQABBLFGERM-UHFFFAOYSA-N n-(5-chloro-1,3-benzodioxol-4-yl)-5-(oxan-4-yloxy)-7-(3-pyrrolidin-1-ylpropoxy)quinazolin-4-amine Chemical compound ClC1=CC=C2OCOC2=C1NC(C1=C(OC2CCOCC2)C=2)=NC=NC1=CC=2OCCCN1CCCC1 HLILQABBLFGERM-UHFFFAOYSA-N 0.000 claims 2
- NNTCPBYVAUSUOH-UHFFFAOYSA-N n-(5-chloro-1,3-benzodioxol-4-yl)-7-[3-(4-methylpiperazin-1-yl)propoxy]-5-(oxan-4-yloxy)quinazolin-4-amine Chemical compound C1CN(C)CCN1CCCOC1=CC(OC2CCOCC2)=C(C(NC=2C(=CC=C3OCOC3=2)Cl)=NC=N2)C2=C1 NNTCPBYVAUSUOH-UHFFFAOYSA-N 0.000 claims 2
- 125000004430 oxygen atom Chemical group O* 0.000 claims 2
- OUKYUETWWIPKQR-UHFFFAOYSA-N saracatinib Chemical compound C1CN(C)CCN1CCOC1=CC(OC2CCOCC2)=C(C(NC=2C(=CC=C3OCOC3=2)Cl)=NC=N2)C2=C1 OUKYUETWWIPKQR-UHFFFAOYSA-N 0.000 claims 2
- 230000007017 scission Effects 0.000 claims 2
- VCVITBJRYVJDMQ-DEOSSOPVSA-N (2s)-1-[2-[4-(2-bromo-5-methoxyanilino)-5-(oxan-4-yloxy)quinazolin-7-yl]oxyethyl]-n-methylpyrrolidine-2-carboxamide Chemical compound CNC(=O)[C@@H]1CCCN1CCOC1=CC(OC2CCOCC2)=C(C(NC=2C(=CC=C(OC)C=2)Br)=NC=N2)C2=C1 VCVITBJRYVJDMQ-DEOSSOPVSA-N 0.000 claims 1
- CZVCRAPDCDORMP-UHFFFAOYSA-N 1-[4-(2-chloro-5-methoxyanilino)-5-(oxan-4-yloxy)quinazolin-7-yl]oxy-3-(4-methylpiperazin-1-yl)propan-2-ol Chemical compound COC1=CC=C(Cl)C(NC=2C3=C(OC4CCOCC4)C=C(OCC(O)CN4CCN(C)CC4)C=C3N=CN=2)=C1 CZVCRAPDCDORMP-UHFFFAOYSA-N 0.000 claims 1
- BDKVXBWNXMYXMM-UHFFFAOYSA-N 1-[4-(2-chloro-5-methoxyanilino)-5-(oxan-4-yloxy)quinazolin-7-yl]oxy-3-morpholin-4-ylpropan-2-ol Chemical compound COC1=CC=C(Cl)C(NC=2C3=C(OC4CCOCC4)C=C(OCC(O)CN4CCOCC4)C=C3N=CN=2)=C1 BDKVXBWNXMYXMM-UHFFFAOYSA-N 0.000 claims 1
- MJPPGVVIDGQOQT-UHFFFAOYSA-N 2-bromo-5-(2-bromo-2-nitroethenyl)furan Chemical compound [O-][N+](=O)C(Br)=CC1=CC=C(Br)O1 MJPPGVVIDGQOQT-UHFFFAOYSA-N 0.000 claims 1
- MDNWOSOZYLHTCG-UHFFFAOYSA-N Dichlorophen Chemical compound OC1=CC=C(Cl)C=C1CC1=CC(Cl)=CC=C1O MDNWOSOZYLHTCG-UHFFFAOYSA-N 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 230000029936 alkylation Effects 0.000 claims 1
- 238000005804 alkylation reaction Methods 0.000 claims 1
- 125000005530 alkylenedioxy group Chemical group 0.000 claims 1
- 125000003277 amino group Chemical group 0.000 claims 1
- 230000001740 anti-invasion Effects 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 238000007796 conventional method Methods 0.000 claims 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- VSCFUBQXHXHWBU-UHFFFAOYSA-N n-(2,4-dichloro-5-methoxyphenyl)-5-(oxan-4-yloxy)-7-(2-piperidin-1-ylethoxy)quinazolin-4-amine Chemical compound C1=C(Cl)C(OC)=CC(NC=2C3=C(OC4CCOCC4)C=C(OCCN4CCCCC4)C=C3N=CN=2)=C1Cl VSCFUBQXHXHWBU-UHFFFAOYSA-N 0.000 claims 1
- RIDMECZKUSOYKF-UHFFFAOYSA-N n-(2,4-dichloro-5-methoxyphenyl)-5-(oxan-4-yloxy)-7-(2-pyrrolidin-1-ylethoxy)quinazolin-4-amine Chemical compound C1=C(Cl)C(OC)=CC(NC=2C3=C(OC4CCOCC4)C=C(OCCN4CCCC4)C=C3N=CN=2)=C1Cl RIDMECZKUSOYKF-UHFFFAOYSA-N 0.000 claims 1
- BLIYFWIFLLWOIW-UHFFFAOYSA-N n-(2,4-dichloro-5-methoxyphenyl)-7-(2-morpholin-4-ylethoxy)-5-(oxan-4-yloxy)quinazolin-4-amine Chemical compound C1=C(Cl)C(OC)=CC(NC=2C3=C(OC4CCOCC4)C=C(OCCN4CCOCC4)C=C3N=CN=2)=C1Cl BLIYFWIFLLWOIW-UHFFFAOYSA-N 0.000 claims 1
- PEZRZHSAIHVJIJ-UHFFFAOYSA-N n-(2,4-dichloro-5-methoxyphenyl)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5-(oxan-4-yloxy)quinazolin-4-amine Chemical compound C1=C(Cl)C(OC)=CC(NC=2C3=C(OC4CCOCC4)C=C(OCCN4CCN(C)CC4)C=C3N=CN=2)=C1Cl PEZRZHSAIHVJIJ-UHFFFAOYSA-N 0.000 claims 1
- LWYABZMGKZJVCX-UHFFFAOYSA-N n-(2,4-dichloro-5-methoxyphenyl)-7-methoxy-5-(1-methylpiperidin-4-yl)oxyquinazolin-4-amine Chemical compound C=12C(NC=3C(=CC(Cl)=C(OC)C=3)Cl)=NC=NC2=CC(OC)=CC=1OC1CCN(C)CC1 LWYABZMGKZJVCX-UHFFFAOYSA-N 0.000 claims 1
- WCGMYDZBHJUBAI-UHFFFAOYSA-N n-(2,5-dimethoxyphenyl)-7-methoxy-5-(1-methylpiperidin-4-yl)oxyquinazolin-4-amine Chemical compound COC1=CC=C(OC)C(NC=2C3=C(OC4CCN(C)CC4)C=C(OC)C=C3N=CN=2)=C1 WCGMYDZBHJUBAI-UHFFFAOYSA-N 0.000 claims 1
- AUPJMWGAXBDLAF-UHFFFAOYSA-N n-(2-bromo-5-methoxyphenyl)-5-(oxan-4-yloxy)-7-(2-piperidin-1-ylethoxy)quinazolin-4-amine Chemical compound COC1=CC=C(Br)C(NC=2C3=C(OC4CCOCC4)C=C(OCCN4CCCCC4)C=C3N=CN=2)=C1 AUPJMWGAXBDLAF-UHFFFAOYSA-N 0.000 claims 1
- AIRJDVWSRXGZLJ-UHFFFAOYSA-N n-(2-bromo-5-methoxyphenyl)-5-(oxan-4-yloxy)-7-(2-pyridin-4-yloxyethoxy)quinazolin-4-amine Chemical compound COC1=CC=C(Br)C(NC=2C3=C(OC4CCOCC4)C=C(OCCOC=4C=CN=CC=4)C=C3N=CN=2)=C1 AIRJDVWSRXGZLJ-UHFFFAOYSA-N 0.000 claims 1
- RWCQVHHBOZOVOB-UHFFFAOYSA-N n-(2-bromo-5-methoxyphenyl)-5-(oxan-4-yloxy)-7-(2-pyrrolidin-1-ylethoxy)quinazolin-4-amine Chemical compound COC1=CC=C(Br)C(NC=2C3=C(OC4CCOCC4)C=C(OCCN4CCCC4)C=C3N=CN=2)=C1 RWCQVHHBOZOVOB-UHFFFAOYSA-N 0.000 claims 1
- QHSJVBSZHSXNSA-UHFFFAOYSA-N n-(2-bromo-5-methoxyphenyl)-5-(oxan-4-yloxy)-7-(pyridin-4-ylmethoxy)quinazolin-4-amine Chemical compound COC1=CC=C(Br)C(NC=2C3=C(OC4CCOCC4)C=C(OCC=4C=CN=CC=4)C=C3N=CN=2)=C1 QHSJVBSZHSXNSA-UHFFFAOYSA-N 0.000 claims 1
- RWICHPXUBOMASG-UHFFFAOYSA-N n-(2-bromo-5-methoxyphenyl)-7-(3-methylsulfonylpropoxy)-5-piperidin-4-yloxyquinazolin-4-amine Chemical compound COC1=CC=C(Br)C(NC=2C3=C(OC4CCNCC4)C=C(OCCCS(C)(=O)=O)C=C3N=CN=2)=C1 RWICHPXUBOMASG-UHFFFAOYSA-N 0.000 claims 1
- LXCFBQWFFIUKPN-UHFFFAOYSA-N n-(2-bromo-5-methoxyphenyl)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5-(oxan-4-yloxy)quinazolin-4-amine Chemical compound COC1=CC=C(Br)C(NC=2C3=C(OC4CCOCC4)C=C(OCCN4CCN(C)CC4)C=C3N=CN=2)=C1 LXCFBQWFFIUKPN-UHFFFAOYSA-N 0.000 claims 1
- IXDJANRWLQKZKC-UHFFFAOYSA-N n-(2-bromo-5-methoxyphenyl)-7-methoxy-5-(1-methylpiperidin-4-yl)oxyquinazolin-4-amine Chemical compound COC1=CC=C(Br)C(NC=2C3=C(OC4CCN(C)CC4)C=C(OC)C=C3N=CN=2)=C1 IXDJANRWLQKZKC-UHFFFAOYSA-N 0.000 claims 1
- KBCHXRRWXCXHDE-UHFFFAOYSA-N n-(2-bromo-5-methoxyphenyl)-7-methoxy-5-(piperidin-4-ylmethoxy)quinazolin-4-amine Chemical compound COC1=CC=C(Br)C(NC=2C3=C(OCC4CCNCC4)C=C(OC)C=C3N=CN=2)=C1 KBCHXRRWXCXHDE-UHFFFAOYSA-N 0.000 claims 1
- KFRSXMUSYAQULP-UHFFFAOYSA-N n-(2-bromo-5-methoxyphenyl)-7-phenylmethoxy-5-piperidin-4-yloxyquinazolin-4-amine Chemical compound COC1=CC=C(Br)C(NC=2C3=C(OC4CCNCC4)C=C(OCC=4C=CC=CC=4)C=C3N=CN=2)=C1 KFRSXMUSYAQULP-UHFFFAOYSA-N 0.000 claims 1
- JNYZPLVVZJKPNU-UHFFFAOYSA-N n-(2-chloro-5-methoxyphenyl)-5,7-bis(3-morpholin-4-ylpropoxy)quinazolin-4-amine Chemical compound COC1=CC=C(Cl)C(NC=2C3=C(OCCCN4CCOCC4)C=C(OCCCN4CCOCC4)C=C3N=CN=2)=C1 JNYZPLVVZJKPNU-UHFFFAOYSA-N 0.000 claims 1
- UKFYOXMBPXQXJR-UHFFFAOYSA-N n-(2-chloro-5-methoxyphenyl)-7-(3-morpholin-4-ylpropoxy)-5-(oxan-4-yloxy)quinazolin-4-amine Chemical compound COC1=CC=C(Cl)C(NC=2C3=C(OC4CCOCC4)C=C(OCCCN4CCOCC4)C=C3N=CN=2)=C1 UKFYOXMBPXQXJR-UHFFFAOYSA-N 0.000 claims 1
- DWMMULHPJUKYRJ-UHFFFAOYSA-N n-(2-chloro-5-methoxyphenyl)-7-(3-morpholin-4-ylpropoxy)-5-(oxolan-3-yloxy)quinazolin-4-amine Chemical compound COC1=CC=C(Cl)C(NC=2C3=C(OC4COCC4)C=C(OCCCN4CCOCC4)C=C3N=CN=2)=C1 DWMMULHPJUKYRJ-UHFFFAOYSA-N 0.000 claims 1
- KSOSADFISSODEE-UHFFFAOYSA-N n-(2-chloro-5-methoxyphenyl)-7-[3-(4-methylpiperazin-1-yl)propoxy]-5-(oxan-4-yloxy)quinazolin-4-amine Chemical compound COC1=CC=C(Cl)C(NC=2C3=C(OC4CCOCC4)C=C(OCCCN4CCN(C)CC4)C=C3N=CN=2)=C1 KSOSADFISSODEE-UHFFFAOYSA-N 0.000 claims 1
- YNFZBOQQNNBILJ-UHFFFAOYSA-N n-(2-chloro-5-methoxyphenyl)-7-[3-(4-methylpiperazin-1-yl)propoxy]-5-(oxolan-3-yloxy)quinazolin-4-amine Chemical compound COC1=CC=C(Cl)C(NC=2C3=C(OC4COCC4)C=C(OCCCN4CCN(C)CC4)C=C3N=CN=2)=C1 YNFZBOQQNNBILJ-UHFFFAOYSA-N 0.000 claims 1
- UDMCXVWGJLMNDD-UHFFFAOYSA-N n-(2-chloro-5-methoxyphenyl)-7-methoxy-5-(1-methylpiperidin-4-yl)oxyquinazolin-4-amine Chemical compound COC1=CC=C(Cl)C(NC=2C3=C(OC4CCN(C)CC4)C=C(OC)C=C3N=CN=2)=C1 UDMCXVWGJLMNDD-UHFFFAOYSA-N 0.000 claims 1
- SRUFFEXENVBMCO-UHFFFAOYSA-N n-(3-chloro-1-benzofuran-7-yl)-7-methoxy-5-(1-methylpiperidin-4-yl)oxyquinazolin-4-amine Chemical compound C=12C(NC=3C=4OC=C(Cl)C=4C=CC=3)=NC=NC2=CC(OC)=CC=1OC1CCN(C)CC1 SRUFFEXENVBMCO-UHFFFAOYSA-N 0.000 claims 1
- VCVHFPAOHFDEOW-UHFFFAOYSA-N n-(5-chloro-1,3-benzodioxol-4-yl)-5-(oxan-4-yloxy)-7-(2-piperidin-1-ylethoxy)quinazolin-4-amine Chemical compound ClC1=CC=C2OCOC2=C1NC(C1=C(OC2CCOCC2)C=2)=NC=NC1=CC=2OCCN1CCCCC1 VCVHFPAOHFDEOW-UHFFFAOYSA-N 0.000 claims 1
- UUUXOMVMDSIRMB-UHFFFAOYSA-N n-(5-chloro-1,3-benzodioxol-4-yl)-5-(oxan-4-yloxy)-7-(2-pyridin-4-yloxyethoxy)quinazolin-4-amine Chemical compound ClC1=CC=C2OCOC2=C1NC(C1=C(OC2CCOCC2)C=2)=NC=NC1=CC=2OCCOC1=CC=NC=C1 UUUXOMVMDSIRMB-UHFFFAOYSA-N 0.000 claims 1
- UTOOQZAPEDMMFY-UHFFFAOYSA-N n-(5-chloro-1,3-benzodioxol-4-yl)-5-(oxan-4-yloxy)-7-(piperidin-4-ylmethoxy)quinazolin-4-amine Chemical compound ClC1=CC=C2OCOC2=C1NC(C1=C(OC2CCOCC2)C=2)=NC=NC1=CC=2OCC1CCNCC1 UTOOQZAPEDMMFY-UHFFFAOYSA-N 0.000 claims 1
- WETSNLOXQAQKPO-UHFFFAOYSA-N n-(5-chloro-1,3-benzodioxol-4-yl)-5-cyclopentyloxy-7-(2-pyrrolidin-1-ylethoxy)quinazolin-4-amine Chemical compound ClC1=CC=C2OCOC2=C1NC(C1=C(OC2CCCC2)C=2)=NC=NC1=CC=2OCCN1CCCC1 WETSNLOXQAQKPO-UHFFFAOYSA-N 0.000 claims 1
- QLPARMMDOPNDPN-UHFFFAOYSA-N n-(5-chloro-1,3-benzodioxol-4-yl)-5-piperidin-4-yloxyquinazolin-4-amine Chemical compound ClC1=CC=C2OCOC2=C1NC(C=12)=NC=NC2=CC=CC=1OC1CCNCC1 QLPARMMDOPNDPN-UHFFFAOYSA-N 0.000 claims 1
- YQPAFFIGFWEPLF-UHFFFAOYSA-N n-(5-chloro-1,3-benzodioxol-4-yl)-7-[(1-methylpiperidin-4-yl)methoxy]-5-(oxan-4-yloxy)quinazolin-4-amine Chemical compound C1CN(C)CCC1COC1=CC(OC2CCOCC2)=C(C(NC=2C(=CC=C3OCOC3=2)Cl)=NC=N2)C2=C1 YQPAFFIGFWEPLF-UHFFFAOYSA-N 0.000 claims 1
- PVOAJSAAENFMPF-UHFFFAOYSA-N n-(5-chloro-1,3-benzodioxol-4-yl)-7-fluoro-5-(oxan-4-yloxy)quinazolin-4-amine Chemical compound C=12C(NC=3C(=CC=C4OCOC4=3)Cl)=NC=NC2=CC(F)=CC=1OC1CCOCC1 PVOAJSAAENFMPF-UHFFFAOYSA-N 0.000 claims 1
- VVKSFHCTJLSWTD-UHFFFAOYSA-N n-(5-chloro-1,3-benzodioxol-4-yl)-7-methoxy-5-(1-methylpiperidin-4-yl)oxyquinazolin-4-amine Chemical compound C=12C(NC=3C(=CC=C4OCOC4=3)Cl)=NC=NC2=CC(OC)=CC=1OC1CCN(C)CC1 VVKSFHCTJLSWTD-UHFFFAOYSA-N 0.000 claims 1
- QQZMLTXRSKBBOH-UHFFFAOYSA-N n-(5-chloro-1,3-benzodioxol-4-yl)-7-methoxy-5-(piperidin-4-ylmethoxy)quinazolin-4-amine Chemical compound C=12C(NC=3C(=CC=C4OCOC4=3)Cl)=NC=NC2=CC(OC)=CC=1OCC1CCNCC1 QQZMLTXRSKBBOH-UHFFFAOYSA-N 0.000 claims 1
- RHICODWVWUTRSH-UHFFFAOYSA-N n-(5-chloro-1,3-benzodioxol-4-yl)-7-methoxy-5-piperidin-4-yloxyquinazolin-4-amine Chemical compound C=12C(NC=3C(=CC=C4OCOC4=3)Cl)=NC=NC2=CC(OC)=CC=1OC1CCNCC1 RHICODWVWUTRSH-UHFFFAOYSA-N 0.000 claims 1
- AWTKDKXDACFEHT-UHFFFAOYSA-N n-(5-chloronaphthalen-1-yl)-7-methoxy-5-(1-methylpiperidin-4-yl)oxyquinazolin-4-amine Chemical compound C=12C(NC=3C4=CC=CC(Cl)=C4C=CC=3)=NC=NC2=CC(OC)=CC=1OC1CCN(C)CC1 AWTKDKXDACFEHT-UHFFFAOYSA-N 0.000 claims 1
- GIVSMOJBMDSXHC-UHFFFAOYSA-N n-(5-methoxy-2-pyrrolidin-1-ylphenyl)-7-[3-(4-methylpiperazin-1-yl)propoxy]-5-(oxan-4-yloxy)quinazolin-4-amine Chemical compound N=1C=NC2=CC(OCCCN3CCN(C)CC3)=CC(OC3CCOCC3)=C2C=1NC1=CC(OC)=CC=C1N1CCCC1 GIVSMOJBMDSXHC-UHFFFAOYSA-N 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 125000006367 bivalent amino carbonyl group Chemical group [H]N([*:1])C([*:2])=O 0.000 description 11
- 125000001064 morpholinomethyl group Chemical group [H]C([H])(*)N1C([H])([H])C([H])([H])OC([H])([H])C1([H])[H] 0.000 description 10
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 description 9
- 125000003006 2-dimethylaminoethyl group Chemical group [H]C([H])([H])N(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 9
- 125000004485 2-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])C1([H])* 0.000 description 9
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 9
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 9
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 description 9
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 description 9
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 description 9
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical group CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 9
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 8
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 description 6
- 125000006222 dimethylaminomethyl group Chemical group [H]C([H])([H])N(C([H])([H])[H])C([H])([H])* 0.000 description 6
- 125000004076 pyridyl group Chemical group 0.000 description 6
- 125000005344 pyridylmethyl group Chemical group [H]C1=C([H])C([H])=C([H])C(=N1)C([H])([H])* 0.000 description 6
- 125000006533 methyl amino methyl group Chemical group [H]N(C([H])([H])[H])C([H])([H])* 0.000 description 5
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 4
- QOXOZONBQWIKDA-UHFFFAOYSA-N 3-hydroxypropyl Chemical group [CH2]CCO QOXOZONBQWIKDA-UHFFFAOYSA-N 0.000 description 4
- 125000004575 3-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 4
- 125000001607 1,2,3-triazol-1-yl group Chemical group [*]N1N=NC([H])=C1[H] 0.000 description 3
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 3
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 3
- 125000004487 4-tetrahydropyranyl group Chemical group [H]C1([H])OC([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 3
- DGYIJVNZSDYBOE-UHFFFAOYSA-N [CH2]C1=CC=NC=C1 Chemical group [CH2]C1=CC=NC=C1 DGYIJVNZSDYBOE-UHFFFAOYSA-N 0.000 description 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 3
- 125000006299 oxetan-3-yl group Chemical group [H]C1([H])OC([H])([H])C1([H])* 0.000 description 3
- 125000003626 1,2,4-triazol-1-yl group Chemical group [*]N1N=C([H])N=C1[H] 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- IJUQRYKKOZHJII-UHFFFAOYSA-N 2-(dimethylamino)-2-[(2-ethoxy-2-methoxyethyl)-ethylamino]-2-(ethylamino)-N'-methyl-N-propoxyacetohydrazide Chemical compound COC(CN(CC)C(C(=O)N(NC)OCCC)(N(C)C)NCC)OCC IJUQRYKKOZHJII-UHFFFAOYSA-N 0.000 description 1
- DVOVBGJJSFSOPZ-UHFFFAOYSA-N 2-acetamidopropanamide Chemical compound NC(=O)C(C)NC(C)=O DVOVBGJJSFSOPZ-UHFFFAOYSA-N 0.000 description 1
- 125000004042 4-aminobutyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])N([H])[H] 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 0 Cc1c(*)c(N)c(C)c(N)c1N Chemical compound Cc1c(*)c(N)c(C)c(N)c1N 0.000 description 1
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 1
- QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 description 1
- 229940080818 propionamide Drugs 0.000 description 1
- 125000006308 propyl amino group Chemical group 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP00401581.4 | 2000-06-06 | ||
| EP00401581 | 2000-06-06 | ||
| EP01400297.6 | 2001-02-07 | ||
| EP01400297 | 2001-02-07 | ||
| EP01400565.6 | 2001-03-05 | ||
| EP01400565 | 2001-03-05 | ||
| PCT/GB2001/002424 WO2001094341A1 (en) | 2000-06-06 | 2001-06-01 | Quinazoline derivatives for the treatment of tumours |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2003535859A JP2003535859A (ja) | 2003-12-02 |
| JP2003535859A5 true JP2003535859A5 (enExample) | 2006-02-16 |
| JP3774438B2 JP3774438B2 (ja) | 2006-05-17 |
Family
ID=27223613
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002501890A Expired - Lifetime JP3774438B2 (ja) | 2000-06-06 | 2001-06-01 | 腫瘍の処置用のキナゾリン誘導体 |
Country Status (31)
| Country | Link |
|---|---|
| US (3) | US7049438B2 (enExample) |
| EP (1) | EP1292594B1 (enExample) |
| JP (1) | JP3774438B2 (enExample) |
| KR (2) | KR100807162B1 (enExample) |
| CN (1) | CN100345844C (enExample) |
| AR (1) | AR030937A1 (enExample) |
| AT (1) | ATE275145T1 (enExample) |
| AU (2) | AU2001260482B2 (enExample) |
| BG (1) | BG65836B1 (enExample) |
| BR (1) | BR0111335A (enExample) |
| CA (1) | CA2407371C (enExample) |
| CO (1) | CO5700751A2 (enExample) |
| CZ (1) | CZ301987B6 (enExample) |
| DE (1) | DE60105295T2 (enExample) |
| DK (1) | DK1292594T3 (enExample) |
| EE (1) | EE05481B1 (enExample) |
| ES (1) | ES2225545T3 (enExample) |
| HU (1) | HU229290B1 (enExample) |
| IL (2) | IL152754A0 (enExample) |
| IS (1) | IS2114B (enExample) |
| MX (1) | MXPA02011765A (enExample) |
| MY (1) | MY127369A (enExample) |
| NO (1) | NO324838B1 (enExample) |
| NZ (1) | NZ522204A (enExample) |
| PL (1) | PL210852B1 (enExample) |
| PT (1) | PT1292594E (enExample) |
| SI (1) | SI1292594T1 (enExample) |
| SK (1) | SK286748B6 (enExample) |
| TW (1) | TWI288748B (enExample) |
| UA (1) | UA73993C2 (enExample) |
| WO (1) | WO2001094341A1 (enExample) |
Families Citing this family (242)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002016352A1 (en) | 2000-08-21 | 2002-02-28 | Astrazeneca Ab | Quinazoline derivatives |
| US6849625B2 (en) | 2000-10-13 | 2005-02-01 | Astrazeneca Ab | Quinazoline derivatives with anti-tumour activity |
| AU2001292137A1 (en) | 2000-10-13 | 2002-04-22 | Astrazeneca Ab | Quinazoline derivatives |
| ATE502928T1 (de) | 2000-11-01 | 2011-04-15 | Millennium Pharm Inc | Stickstoffhaltige heterozyklische verbindungen und verfahren zu deren herstellung |
| MXPA03008658A (es) * | 2001-03-23 | 2005-04-11 | Bayer Ag | Inhibidores de rho-cinasa. |
| UY27225A1 (es) * | 2001-03-23 | 2002-10-31 | Bayer Corp | Inhibidores de la rho-quinasa |
| ES2312557T3 (es) | 2001-04-19 | 2009-03-01 | Astrazeneca Ab | Derivados de quinazolina. |
| JP4326328B2 (ja) | 2001-07-16 | 2009-09-02 | アストラゼネカ アクチボラグ | キノリン誘導体及びそれらのチロシンキナーゼ阻害薬としての使用 |
| JP2005515176A (ja) * | 2001-11-03 | 2005-05-26 | アストラゼネカ アクチボラグ | 抗腫瘍剤としてのキナゾリン誘導体 |
| GB0126433D0 (en) * | 2001-11-03 | 2002-01-02 | Astrazeneca Ab | Compounds |
| GB0128108D0 (en) | 2001-11-23 | 2002-01-16 | Astrazeneca Ab | Therapeutic use |
| WO2003047582A1 (en) * | 2001-12-05 | 2003-06-12 | Astrazeneca Ab | Quinoline derivatives as antitumour agents |
| CN1625555A (zh) * | 2002-02-01 | 2005-06-08 | 阿斯特拉曾尼卡有限公司 | 喹唑啉化合物 |
| US6924285B2 (en) | 2002-03-30 | 2005-08-02 | Boehringer Ingelheim Pharma Gmbh & Co. | Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them |
| GB0215823D0 (en) | 2002-07-09 | 2002-08-14 | Astrazeneca Ab | Quinazoline derivatives |
| DE60327323D1 (de) | 2002-07-09 | 2009-06-04 | Astrazeneca Ab | Chinazoline derivative und ihre anwendung in der krebsbehandlung |
| US7576074B2 (en) | 2002-07-15 | 2009-08-18 | Rice Kenneth D | Receptor-type kinase modulators and methods of use |
| GB0225579D0 (en) | 2002-11-02 | 2002-12-11 | Astrazeneca Ab | Chemical compounds |
| US7462623B2 (en) * | 2002-11-04 | 2008-12-09 | Astrazeneca Ab | Quinazoline derivatives as Src tyrosine kinase inhibitors |
| AU2003292435A1 (en) * | 2002-12-23 | 2004-07-14 | Astrazeneca Ab | 4- (pyridin-4-ylamino) -quinazoline derivatives as anti-tumor agents |
| AU2003290279A1 (en) * | 2002-12-23 | 2004-07-14 | Astrazeneca Ab | Quinazoline derivatives |
| GB0307333D0 (en) * | 2003-03-29 | 2003-05-07 | Astrazeneca Ab | Therapeutic agent |
| GB0309850D0 (en) * | 2003-04-30 | 2003-06-04 | Astrazeneca Ab | Quinazoline derivatives |
| GB0310401D0 (en) * | 2003-05-07 | 2003-06-11 | Astrazeneca Ab | Therapeutic agent |
| AU2004253967B2 (en) | 2003-07-03 | 2010-02-18 | Cytovia, Inc. | 4-arylamino-quinazolines as activators of caspases and inducers of apoptosis |
| US8309562B2 (en) | 2003-07-03 | 2012-11-13 | Myrexis, Inc. | Compounds and therapeutical use thereof |
| GB0317665D0 (en) | 2003-07-29 | 2003-09-03 | Astrazeneca Ab | Qinazoline derivatives |
| US7569577B2 (en) * | 2003-09-16 | 2009-08-04 | Astrazeneca Ab | Quinazoline derivatives as tyrosine kinase inhibitors |
| GB0322409D0 (en) | 2003-09-25 | 2003-10-29 | Astrazeneca Ab | Quinazoline derivatives |
| WO2005030140A2 (en) | 2003-09-26 | 2005-04-07 | Exelixis, Inc. | C-met modulators and methods of use |
| GB0326459D0 (en) | 2003-11-13 | 2003-12-17 | Astrazeneca Ab | Quinazoline derivatives |
| ATE413389T1 (de) | 2004-02-03 | 2008-11-15 | Astrazeneca Ab | Chinazolinderivate |
| ME01267B (me) | 2004-05-06 | 2013-06-20 | Warner Lambert Co | 4-fenilaminokinazolin-6-ilamidi |
| GB0412074D0 (en) * | 2004-05-29 | 2004-06-30 | Astrazeneca Ab | Combination product |
| CA2567832A1 (en) * | 2004-06-04 | 2005-12-15 | Astrazeneca Ab | Quinazoline derivatives as erbb receptor tyrosine kinases |
| UY29198A1 (es) * | 2004-11-09 | 2006-05-31 | Cancer Rec Tech Ltd | Derivados sustituidos de quinazolinona y derivados sustituidos de quinazolina-2, 4-diona, composiciones conteniéndolos, procedimientos de preparación y aplicaciones |
| CN101124228B (zh) * | 2004-12-14 | 2011-06-15 | 阿斯利康(瑞典)有限公司 | 用作抗肿瘤药物的吡唑并嘧啶化合物 |
| GB0427697D0 (en) * | 2004-12-17 | 2005-01-19 | Astrazeneca Ab | Chemical process |
| US8258145B2 (en) | 2005-01-03 | 2012-09-04 | Myrexis, Inc. | Method of treating brain cancer |
| EP1833482A4 (en) | 2005-01-03 | 2011-02-16 | Myriad Genetics Inc | COMPOUNDS AND ITS THERAPEUTIC USE |
| WO2006081741A1 (en) * | 2005-02-05 | 2006-08-10 | Piaoyang Sun | Quinazoline compounds or their medical salts and preparation and medical usage thereof |
| CN1854130B (zh) * | 2005-04-15 | 2011-04-20 | 中国医学科学院药物研究所 | 喹唑啉衍生物、及其制法和药物组合物与用途 |
| GB0508715D0 (en) * | 2005-04-29 | 2005-06-08 | Astrazeneca Ab | Chemical compounds |
| ATE443053T1 (de) * | 2005-12-02 | 2009-10-15 | Astrazeneca Ab | Als inhibitoren von erbb-tyrosinkinase verwendete chinazoleinderivate |
| WO2007063291A1 (en) | 2005-12-02 | 2007-06-07 | Astrazeneca Ab | 4-anilino-substituted quinazoline derivatives as tyrosine kinase inhibitors |
| UY30183A1 (es) | 2006-03-02 | 2007-10-31 | Astrazeneca Ab | Derivados de quinolina |
| TW200813091A (en) | 2006-04-10 | 2008-03-16 | Amgen Fremont Inc | Targeted binding agents directed to uPAR and uses thereof |
| CL2007002225A1 (es) | 2006-08-03 | 2008-04-18 | Astrazeneca Ab | Agente de union especifico para un receptor del factor de crecimiento derivado de plaquetas (pdgfr-alfa); molecula de acido nucleico que lo codifica; vector y celula huesped que la comprenden; conjugado que comprende al agente; y uso del agente de un |
| EP1921070A1 (de) | 2006-11-10 | 2008-05-14 | Boehringer Ingelheim Pharma GmbH & Co. KG | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung |
| JP5622393B2 (ja) | 2006-12-15 | 2014-11-12 | アブラクシスバイオサイエンス リミテッド ライアビリティー カンパニー | トリアジン誘導体類及びそれらの治療応用 |
| US20100173426A1 (en) * | 2006-12-19 | 2010-07-08 | Johnson Faye M | Biomaker identifying the reactivation of stat3 after src inhibition |
| EA200901041A1 (ru) | 2007-02-06 | 2010-02-26 | Бёрингер Ингельхайм Интернациональ Гмбх | Бициклические гетероциклы, содержащие эти соединения лекарственные средства, их применение и способ их получения |
| JPWO2008114819A1 (ja) | 2007-03-20 | 2010-07-08 | 大日本住友製薬株式会社 | 新規アデニン化合物 |
| JP4705695B2 (ja) | 2007-10-11 | 2011-06-22 | アストラゼネカ アクチボラグ | プロテインキナーゼｂ阻害剤としてのピロロ［２，３−ｄ］ピリミジン誘導体 |
| NZ585357A (en) | 2007-10-29 | 2012-02-24 | Natco Pharma Ltd | Novel 4-(tetrazol-5-yl)-quinazoline derivatives as anti cancer agents |
| WO2009068906A2 (en) * | 2007-11-26 | 2009-06-04 | Astrazeneca Ab | Combinations comprising zd4054 and a src family kinase inhibitor 172 |
| RS52573B (sr) | 2008-02-07 | 2013-04-30 | Boehringer Ingelheim International Gmbh | Spirociklični heterocikli, lekovi koji sadrže navedeno jedinjenje, njihova primena i postupak za njihovu proizvodnju |
| US7829574B2 (en) * | 2008-05-09 | 2010-11-09 | Hutchison Medipharma Enterprises Limited | Substituted quinazoline compounds and their use in treating angiogenesis-related diseases |
| BRPI0912170A2 (pt) | 2008-05-13 | 2015-10-13 | Astrazeneca Ab | composto, forma a, processo para a preparação da mesma, composição farmacêutica, uso de um composto, e, método para tratar um câncer em um animal de sangue quente |
| CA2733153C (en) | 2008-08-08 | 2016-11-08 | Boehringer Ingelheim International Gmbh | Cyclohexyloxy substituted heterocycles, pharmaceutical compositions containing these compounds and processes for preparing them |
| US9256904B1 (en) | 2008-08-14 | 2016-02-09 | Experian Information Solutions, Inc. | Multi-bureau credit file freeze and unfreeze |
| US20100069340A1 (en) * | 2008-09-11 | 2010-03-18 | Wyeth | Pharmaceutical compositions of an src kinase inhibitor and an aromatase inhibitor |
| MX2011002837A (es) | 2008-09-19 | 2011-07-29 | Medimmune Llc | Anticuerpos dirigidos al ligando tipo delta 4 (dll4) y usos de los mismos. |
| CN101723906B (zh) * | 2008-10-10 | 2011-09-28 | 山西仁源堂药业有限公司 | 一种化合物、含该化合物的药物组合物及制备方法和用途 |
| TW201028410A (en) | 2008-12-22 | 2010-08-01 | Astrazeneca Ab | Chemical compounds 610 |
| AU2009331528A1 (en) | 2008-12-23 | 2011-08-11 | Astrazeneca Ab | Targeted binding agents directed to alpha5beta1 and uses thereof |
| DK2387563T4 (da) | 2009-01-16 | 2022-07-18 | Exelixis Inc | Malatsalt af n-(4-{ [ 6, 7-bis(methyloxy)quinolin-4-yl]oxy}phenyl-n'-(4-fluorphenyl)cyclopropan-1,1-dicarboxamid, og krystallinske former deraf til behandling af cancer |
| WO2010089580A1 (en) | 2009-02-06 | 2010-08-12 | Astrazeneca Ab | Use of a mct1 inhibitor in the treatment of cancers expressing mct1 over mct4 |
| EA019647B1 (ru) | 2009-02-10 | 2014-05-30 | Астразенека Аб | ПРОИЗВОДНЫЕ ТРИАЗОЛО[4,3-b]ПИРИДАЗИНА И ИХ ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ РАКА ПРЕДСТАТЕЛЬНОЙ ЖЕЛЕЗЫ |
| GB0905127D0 (en) | 2009-03-25 | 2009-05-06 | Pharminox Ltd | Novel prodrugs |
| US8389580B2 (en) | 2009-06-02 | 2013-03-05 | Duke University | Arylcyclopropylamines and methods of use |
| AU2010258853B2 (en) | 2009-06-09 | 2014-07-31 | Nantbio, Inc. | Triazine derivatives and their therapeutical applications |
| BRPI1011319A2 (pt) | 2009-06-09 | 2016-06-21 | California Capital Equity Llc | derivados de triazina benzil-substituídos e suas aplicações terapêuticas |
| US20100317593A1 (en) | 2009-06-12 | 2010-12-16 | Astrazeneca Ab | 2,3-dihydro-1h-indene compounds |
| UA108618C2 (uk) | 2009-08-07 | 2015-05-25 | Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку | |
| US8399460B2 (en) | 2009-10-27 | 2013-03-19 | Astrazeneca Ab | Chromenone derivatives |
| BR112012011518B8 (pt) | 2009-11-18 | 2023-01-10 | Astrazeneca Ab | Compostos, composição farmacêutica, kit e usos de um composto |
| NZ599405A (en) | 2009-11-24 | 2014-09-26 | Medimmune Ltd | Targeted binding agents against b7-h1 |
| WO2011068233A1 (en) | 2009-12-03 | 2011-06-09 | Dainippon Sumitomo Pharma Co., Ltd. | Imidazoquinolines which act via toll - like receptors (tlr) |
| ES2857626T3 (es) | 2010-01-15 | 2021-09-29 | Suzhou Neupharma Co Ltd | Ciertas entidades químicas, composiciones y métodos |
| WO2011089416A1 (en) | 2010-01-19 | 2011-07-28 | Astrazeneca Ab | Pyrazine derivatives |
| WO2011095807A1 (en) | 2010-02-07 | 2011-08-11 | Astrazeneca Ab | Combinations of mek and hh inhibitors |
| SA111320519B1 (ar) | 2010-06-11 | 2014-07-02 | Astrazeneca Ab | مركبات بيريميدينيل للاستخدام كمثبطات atr |
| TWI535712B (zh) | 2010-08-06 | 2016-06-01 | 阿斯特捷利康公司 | 化合物 |
| CN102656179B (zh) | 2010-08-28 | 2015-07-29 | 苏州润新生物科技有限公司 | 蟾蜍灵衍生物、其药物组合物及用途 |
| GB201016442D0 (en) | 2010-09-30 | 2010-11-17 | Pharminox Ltd | Novel acridine derivatives |
| WO2012066335A1 (en) | 2010-11-19 | 2012-05-24 | Astrazeneca Ab | Phenol compounds als toll -like receptor 7 agonists |
| EP2640716A1 (en) | 2010-11-19 | 2013-09-25 | Dainippon Sumitomo Pharma Co., Ltd. | Cyclic amide compounds and their use in the treatment of disease |
| WO2012067269A1 (en) | 2010-11-19 | 2012-05-24 | Dainippon Sumitomo Pharma Co., Ltd. | Aminoalkoxyphenyl compounds and their use in the treatment of disease |
| WO2012066336A1 (en) | 2010-11-19 | 2012-05-24 | Astrazeneca Ab | Benzylamine compounds as toll -like receptor 7 agonists |
| US9012464B2 (en) | 2010-11-25 | 2015-04-21 | Ratiopharm Gmbh | Salts and polymorphic forms of Afatinib |
| EP2670763B1 (en) | 2011-02-02 | 2018-08-01 | Suzhou Neupharma Co., Ltd | Certain chemical entities, compositions, and methods |
| JP5937112B2 (ja) | 2011-02-17 | 2016-06-22 | カンサー・セラピューティクス・シーアールシー・プロプライエタリー・リミテッドＣａｎｃｅｒ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｃｒｃ Ｐｔｙ Ｌｉｍｉｔｅｄ | 選択的ｆａｋ阻害剤 |
| ES2691673T3 (es) | 2011-02-17 | 2018-11-28 | Cancer Therapeutics Crc Pty Limited | Inhibidores de Fak |
| GB201104267D0 (en) | 2011-03-14 | 2011-04-27 | Cancer Rec Tech Ltd | Pyrrolopyridineamino derivatives |
| UY34013A (es) | 2011-04-13 | 2012-11-30 | Astrazeneca Ab | ?compuestos de cromenona con actividad anti-tumoral?. |
| WO2012175991A1 (en) | 2011-06-24 | 2012-12-27 | Pharminox Limited | Fused pentacyclic anti - proliferative compounds |
| PT3009431T (pt) | 2011-07-27 | 2017-12-26 | Astrazeneca Ab | Compostos de 2-(2,4,5-anilino-substituídos)pirimidina como moduladores úteis do egfr para o tratamento do cancro |
| ES2725790T3 (es) | 2011-08-26 | 2019-09-27 | Neupharma Inc | Algunas entidades químicas, composiciones, y métodos |
| WO2013040515A1 (en) | 2011-09-14 | 2013-03-21 | Neupharma, Inc. | Certain chemical entities, compositions, and methods |
| WO2013043935A1 (en) | 2011-09-21 | 2013-03-28 | Neupharma, Inc. | Certain chemical entites, compositions, and methods |
| US20140235573A1 (en) | 2011-09-29 | 2014-08-21 | The University Of Liverpool | Prevention and/or treatment of cancer and/or cancer metastasis |
| US9249111B2 (en) | 2011-09-30 | 2016-02-02 | Neupharma, Inc. | Substituted quinoxalines as B-RAF kinase inhibitors |
| US20130178520A1 (en) | 2011-12-23 | 2013-07-11 | Duke University | Methods of treatment using arylcyclopropylamine compounds |
| WO2013112950A2 (en) | 2012-01-25 | 2013-08-01 | Neupharma, Inc. | Certain chemical entities, compositions, and methods |
| WO2013165924A1 (en) | 2012-04-29 | 2013-11-07 | Neupharma, Inc. | Certain chemical entities, compositions, and methods |
| GB201211021D0 (en) | 2012-06-21 | 2012-08-01 | Cancer Rec Tech Ltd | Pharmaceutically active compounds |
| HK1209105A1 (en) | 2012-08-17 | 2016-03-24 | Cancer Therapeutics Crc Pty Limited | Vegfr3 inhibitors |
| WO2014041349A1 (en) | 2012-09-12 | 2014-03-20 | Cancer Therapeutics Crc Pty Ltd | Tetrahydropyran-4-ylethylamino- or tetrahydropyranyl-4-ethyloxy-pyrimidines or -pyridazines as isoprenylcysteincarboxymethyl transferase inhibitors |
| EP2897618B1 (en) | 2012-09-24 | 2021-11-17 | Neupharma, Inc. | Certain chemical entities, compositions, and methods |
| EP2916838B1 (en) | 2012-11-12 | 2019-03-13 | Neupharma, Inc. | Certain chemical entities, compositions, and methods |
| WO2014117274A1 (en) | 2013-01-31 | 2014-08-07 | Neomed Institute | Imidazopyridine compounds and uses thereof |
| AU2014216178B2 (en) | 2013-02-15 | 2018-06-28 | KALA BIO, Inc. | Therapeutic compounds and uses thereof |
| EP2958895B1 (en) | 2013-02-20 | 2020-08-19 | Kala Pharmaceuticals, Inc. | Therapeutic compounds and uses thereof |
| US9688688B2 (en) | 2013-02-20 | 2017-06-27 | Kala Pharmaceuticals, Inc. | Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof |
| CN113398147A (zh) | 2013-03-15 | 2021-09-17 | 纽罗森特里亚股份有限公司 | 用于癌症的镁组合物及其用途 |
| AR095443A1 (es) | 2013-03-15 | 2015-10-14 | Fundación Centro Nac De Investig Oncológicas Carlos Iii | Heterociclos condensados con acción sobre atr |
| EP3004073A1 (en) | 2013-06-07 | 2016-04-13 | Université catholique de Louvain | 3-carboxy substituted coumarin derivatives with a potential utility for the treatment of cancer diseases |
| AU2014308616B2 (en) | 2013-08-23 | 2018-12-06 | Neupharma, Inc. | Certain chemical entities, compositions, and methods |
| US9890173B2 (en) | 2013-11-01 | 2018-02-13 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
| CA2928658A1 (en) | 2013-11-01 | 2015-05-07 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
| CN105916506B (zh) | 2013-11-20 | 2020-01-07 | 圣诺康生命科学公司 | 作为tam家族激酶抑制剂的喹唑啉衍生物 |
| GB201403536D0 (en) | 2014-02-28 | 2014-04-16 | Cancer Rec Tech Ltd | Inhibitor compounds |
| EP3194572B1 (en) | 2014-07-30 | 2023-10-25 | Yeda Research and Development Co. Ltd. | Media for culturing pluripotent stem cells |
| MA41179A (fr) | 2014-12-19 | 2017-10-24 | Cancer Research Tech Ltd | Composés inhibiteurs de parg |
| GB201501870D0 (en) | 2015-02-04 | 2015-03-18 | Cancer Rec Tech Ltd | Autotaxin inhibitors |
| GB201502020D0 (en) | 2015-02-06 | 2015-03-25 | Cancer Rec Tech Ltd | Autotaxin inhibitory compounds |
| WO2016130897A1 (en) | 2015-02-13 | 2016-08-18 | Yu Paul B | Methods and compositions for the treatment or prevention of abnormal bone formation in a soft tissue |
| GB201510019D0 (en) | 2015-06-09 | 2015-07-22 | Cancer Therapeutics Crc Pty Ltd | Compounds |
| USRE49850E1 (en) | 2015-08-04 | 2024-02-27 | Aucentra Therapeutics Pty Ltd | N-(pyridin-2-yl)-4-(thiazol-5-yl)pyrimidin-2-amine derivatives as therapeutic compounds |
| EP4071174A1 (en) | 2016-02-15 | 2022-10-12 | AstraZeneca AB | Methods comprising fixed intermittent dosing of cediranib |
| EP3442535B1 (en) | 2016-04-15 | 2022-06-01 | Cancer Research Technology Limited | Heterocyclic compounds as ret kinase inhibitors |
| GB2554333A (en) | 2016-04-26 | 2018-04-04 | Big Dna Ltd | Combination therapy |
| CN107459519A (zh) | 2016-06-06 | 2017-12-12 | 上海艾力斯医药科技有限公司 | 稠合嘧啶哌啶环衍生物及其制备方法和应用 |
| KR101706346B1 (ko) | 2016-06-09 | 2017-03-13 | 서동균 | 건축물의 외벽 마감재 고정장치 |
| EP4006035B1 (en) | 2016-08-15 | 2023-11-22 | Neupharma, Inc. | Quinazoline derivatives as tyrosine kinase inhibitors for the treatment of cancer |
| CA3036340A1 (en) | 2016-09-08 | 2018-03-15 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
| CA3036065A1 (en) | 2016-09-08 | 2018-03-15 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
| AU2017324713B2 (en) | 2016-09-08 | 2020-08-13 | KALA BIO, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
| CN110036006B (zh) | 2016-09-22 | 2022-12-13 | 癌症研究科技有限公司 | 嘧啶酮衍生物的制备和用途 |
| GB201617103D0 (en) | 2016-10-07 | 2016-11-23 | Cancer Research Technology Limited | Compound |
| US10786502B2 (en) | 2016-12-05 | 2020-09-29 | Apros Therapeutics, Inc. | Substituted pyrimidines containing acidic groups as TLR7 modulators |
| EP3548478B1 (en) | 2016-12-05 | 2021-11-17 | Apros Therapeutics, Inc. | Pyrimidine compounds containing acidic groups |
| WO2018141002A2 (en) | 2017-02-01 | 2018-08-09 | University Of South Australia | DERIVATIVES OF N-CYCLOALKYL/HETEROCYCLOALKYL-4-(IMIDAZO [1,2-a]PYRIDINE)PYRIMIDIN-2-AMINE AS THERAPEUTIC AGENTS |
| GB201704325D0 (en) | 2017-03-17 | 2017-05-03 | Argonaut Therapeutics Ltd | Compounds |
| GB201705971D0 (en) | 2017-04-13 | 2017-05-31 | Cancer Res Tech Ltd | Inhibitor compounds |
| CN111163839B (zh) | 2017-05-26 | 2024-05-28 | 癌症研究科技有限公司 | 苯并咪唑酮衍生的bcl6抑制剂 |
| ES2975661T3 (es) | 2017-05-26 | 2024-07-11 | Cancer Research Tech Ltd | Inhibidores de BCL6 derivados de la 2-quinolona |
| EP3648797A1 (en) | 2017-07-05 | 2020-05-13 | EPOS-Iasis Research and Development, Ltd | Multifunctional conjugates |
| CN111278840B (zh) | 2017-08-18 | 2023-11-17 | 癌症研究科技有限公司 | 吡咯并[2，3-b]吡啶化合物及其治疗癌症的用途 |
| NL2019801B1 (en) | 2017-10-25 | 2019-05-02 | Univ Leiden | Delivery vectors |
| CN107814793A (zh) * | 2017-12-30 | 2018-03-20 | 胡张艳 | 一种小分子Src酪氨酸激酶抑制剂塞卡替尼及其中间体的制备方法 |
| CN107987064A (zh) * | 2017-12-30 | 2018-05-04 | 王兆举 | 一种治疗骨癌的药物塞卡替尼的制备方法 |
| EP3740484B1 (en) | 2018-01-15 | 2024-09-11 | Aucentra Therapeutics Pty Ltd | 5-(pyrimidin-4-yl)thiazol-2-yl urea derivatives as therapeutic agents |
| GB201801128D0 (en) | 2018-01-24 | 2018-03-07 | Univ Oxford Innovation Ltd | Compounds |
| US11465975B2 (en) | 2018-02-08 | 2022-10-11 | Neupharma, Inc | Certain chemical entities, compositions, and methods |
| WO2019175093A1 (en) | 2018-03-12 | 2019-09-19 | Astrazeneca Ab | Method for treating lung cancer |
| WO2019196622A1 (zh) * | 2018-04-09 | 2019-10-17 | 威尚（上海）生物医药有限公司 | 具有穿过血脑屏障能力的5取代二氟哌啶化合物 |
| CN110357858B (zh) | 2018-04-09 | 2022-02-18 | 威尚（上海）生物医药有限公司 | 具有穿过血脑屏障能力的5取代二氟哌啶化合物 |
| JP7493454B2 (ja) | 2018-04-13 | 2024-05-31 | キャンサー・リサーチ・テクノロジー・リミテッド | Ｂｃｌ６阻害剤 |
| GB201809102D0 (en) | 2018-06-04 | 2018-07-18 | Univ Oxford Innovation Ltd | Compounds |
| AR114910A1 (es) | 2018-06-04 | 2020-10-28 | Apros Therapeutics Inc | Compuestos de pirimidina que contienen grupos ácidos |
| GB201810092D0 (en) | 2018-06-20 | 2018-08-08 | Ctxt Pty Ltd | Compounds |
| GB201810581D0 (en) | 2018-06-28 | 2018-08-15 | Ctxt Pty Ltd | Compounds |
| GB201819126D0 (en) | 2018-11-23 | 2019-01-09 | Cancer Research Tech Ltd | Inhibitor compounds |
| EP3914698B1 (en) | 2019-01-23 | 2024-12-11 | Yeda Research and Development Co. Ltd | Culture media for pluripotent stem cells |
| CN113727716A (zh) | 2019-02-25 | 2021-11-30 | 贝卢斯医疗咳嗽病公司 | 采用p2x3调节剂的治疗 |
| ES2994095T3 (en) | 2019-02-27 | 2025-01-17 | Astrazeneca Ab | Saracatinib for use in the treatment of idiopathic pulmonary fibrosis |
| MX2021011810A (es) | 2019-03-29 | 2021-10-26 | Astrazeneca Ab | Osimertinib para su uso en el tratamiento de cancer de pulmon de celulas no peque?as. |
| JP7762957B2 (ja) | 2019-04-05 | 2025-10-31 | ストーム・セラピューティクス・リミテッド | Ｍｅｔｔｌ３阻害化合物 |
| GB201905328D0 (en) | 2019-04-15 | 2019-05-29 | Azeria Therapeutics Ltd | Inhibitor compounds |
| GB201908885D0 (en) | 2019-06-20 | 2019-08-07 | Storm Therapeutics Ltd | Therapeutic compounds |
| AU2020335054A1 (en) | 2019-08-31 | 2022-03-24 | Etern Biopharma (Shanghai) Co., Ltd. | Pyrazole derivative for FGFR inhibitor and preparation method therefor |
| WO2021055744A1 (en) | 2019-09-20 | 2021-03-25 | Ideaya Biosciences, Inc. | 4-substituted indole and indazole sulfonamido derivatives as parg inhibitors |
| GB201913988D0 (en) | 2019-09-27 | 2019-11-13 | Celleron Therapeutics Ltd | Novel treatment |
| GB201914860D0 (en) | 2019-10-14 | 2019-11-27 | Cancer Research Tech Ltd | Inhibitor compounds |
| GB201915828D0 (en) | 2019-10-31 | 2019-12-18 | Cancer Research Tech Ltd | Compounds, compositions and therapeutic uses thereof |
| GB201915829D0 (en) | 2019-10-31 | 2019-12-18 | Cancer Research Tech Ltd | Compounds, compositions and therapeutic uses thereof |
| GB201915831D0 (en) | 2019-10-31 | 2019-12-18 | Cancer Research Tech Ltd | Compounds, compositions and therapeutic uses thereof |
| AU2020394867A1 (en) | 2019-12-02 | 2022-05-26 | Storm Therapeutics Limited | Polyheterocyclic compounds as METTL3 inhibitors |
| GB202004960D0 (en) | 2020-04-03 | 2020-05-20 | Kinsenus Ltd | Inhibitor compounds |
| US20230183197A1 (en) | 2020-06-01 | 2023-06-15 | Neophore Limited | Inhibitors of mlh1 and/or pms2 for cancer treatment |
| GB202012482D0 (en) | 2020-08-11 | 2020-09-23 | Univ Of Huddersfield | Novel compounds and therapeutic uses thereof |
| GB202012969D0 (en) | 2020-08-19 | 2020-09-30 | Univ Of Oxford | Inhibitor compounds |
| WO2022074379A1 (en) | 2020-10-06 | 2022-04-14 | Storm Therapeutics Limited | Mettl3 inhibitory compounds |
| WO2022074391A1 (en) | 2020-10-08 | 2022-04-14 | Storm Therapeutics Limited | Compounds inhibitors of mettl3 |
| GB202102895D0 (en) | 2021-03-01 | 2021-04-14 | Cambridge Entpr Ltd | Novel compounds, compositions and therapeutic uses thereof |
| BR112023024040A2 (pt) | 2021-05-17 | 2024-02-06 | Hk Inno N Corp | Composto, o isômero óptico do mesmo, o solvato do mesmo, o hidrato do mesmo ou o sal farmaceuticamente aceitável do mesmo e seu uso, composição farmacêutica que compreende o dito composto, composição de alimento funcional para a saúde e preparação combinada |
| GB202107907D0 (en) | 2021-06-02 | 2021-07-14 | Storm Therapeutics Ltd | Combination therapies |
| GB202108383D0 (en) | 2021-06-11 | 2021-07-28 | Argonaut Therapeutics Ltd | Compounds useful in the treatment or prevention of a prmt5-mediated disorder |
| GB202110373D0 (en) | 2021-07-19 | 2021-09-01 | Neophore Ltd | Inhibitor compounds |
| US20250002491A1 (en) | 2021-10-04 | 2025-01-02 | Forx Therapeutics Ag | N,n-dimethyl-4-(7-(n-(1-methylcyclopropyl)sulfamoyl)-imidazo[1,5-a]pyridin-5-yl)piperazine-1-carboxamide derivatives and the corresponding pyrazolo[1,5-a]pyridine derivatives as parg inhibitors for the treatment of cancer |
| WO2023057389A1 (en) | 2021-10-04 | 2023-04-13 | Forx Therapeutics Ag | Parg inhibitory compounds |
| GB202117224D0 (en) | 2021-11-29 | 2022-01-12 | Neophore Ltd | Inhibitor compounds |
| GB202117225D0 (en) | 2021-11-29 | 2022-01-12 | Neophore Ltd | Protac compounds |
| GB202202006D0 (en) | 2022-02-15 | 2022-03-30 | Chancellor Masters And Scholars Of The Univ Of Oxford | Anti-cancer treatment |
| GB202202199D0 (en) | 2022-02-18 | 2022-04-06 | Cancer Research Tech Ltd | Compounds |
| WO2023175184A1 (en) | 2022-03-17 | 2023-09-21 | Forx Therapeutics Ag | 2,4-dioxo-1,4-dihydroquinazoline derivatives as parg inhibitors for the treatment of cancer |
| WO2023175185A1 (en) | 2022-03-17 | 2023-09-21 | Forx Therapeutics Ag | 2,4-dioxo-1,4-dihydroquinazoline derivatives as parg inhibitors for the treatment of cancer |
| GB202204935D0 (en) | 2022-04-04 | 2022-05-18 | Cambridge Entpr Ltd | Nanoparticles |
| CA3250036A1 (en) | 2022-05-11 | 2023-11-16 | Cancer Research Tech Ltd | IKK INHIBITORS |
| GB202209404D0 (en) | 2022-06-27 | 2022-08-10 | Univ Of Sussex | Compounds |
| EP4565592A1 (en) | 2022-08-01 | 2025-06-11 | Neupharma, Inc. | Crystalline salts of crystalline salts of (3s,5r,8r,9s,10s,13r,14s,17r)-14-hydroxy-10,13-dimethyl-17-(2- oxo-2h-pyran-5-yl)hexadecahydro-1h-cyclopenta[a]phenanthren-3-yl piperazine-1-carboxylate |
| GB202213167D0 (en) | 2022-09-08 | 2022-10-26 | Cambridge Entpr Ltd | Novel compounds, compositions and therapeutic uses thereof |
| GB202213166D0 (en) | 2022-09-08 | 2022-10-26 | Cambridge Entpr Ltd | Novel compounds, compositions and therapeutic uses thereof |
| GB202213162D0 (en) | 2022-09-08 | 2022-10-26 | Cambridge Entpr Ltd | Prodrugs |
| GB202213163D0 (en) | 2022-09-08 | 2022-10-26 | Cambridge Entpr Ltd | Novel compounds, compositions and therapeutic uses thereof |
| GB202213164D0 (en) | 2022-09-08 | 2022-10-26 | Cambridge Entpr Ltd | Novel compounds, compositions and therapeutic uses thereof |
| WO2024074497A1 (en) | 2022-10-03 | 2024-04-11 | Forx Therapeutics Ag | Parg inhibitory compound |
| WO2024094962A1 (en) | 2022-11-02 | 2024-05-10 | Cancer Research Technology Limited | Pyrido[2,3-d]pyrimidin-2-amine derivatives as egfr inhibitors for the treatment of cancer |
| WO2024094963A1 (en) | 2022-11-02 | 2024-05-10 | Cancer Research Technology Limited | 2-amino-pyrido[2,3-d]pyrimidin-7(8h)-one and 7-amino-1-pyrimido[4,5-d]pyrimidin-2(1 h)-one derivatives as egfr inhibitors for the treatment of cancer |
| GB202218672D0 (en) | 2022-12-12 | 2023-01-25 | Storm Therapeutics Ltd | Inhibitory compounds |
| GB202300881D0 (en) | 2023-01-20 | 2023-03-08 | Neophore Ltd | Inhibitor compounds |
| WO2024173453A1 (en) | 2023-02-14 | 2024-08-22 | Ideaya Biosciences, Inc. | Heteroaryl-substituted imidazopyridine compounds |
| WO2024173524A1 (en) | 2023-02-14 | 2024-08-22 | Ideaya Biosciences, Inc. | Heteroaryl-substituted benzimidazole compounds |
| WO2024173530A1 (en) | 2023-02-14 | 2024-08-22 | Ideaya Biosciences, Inc. | Heteroaryl-substituted pyrazolo/imidazo pyridine compounds |
| WO2024173514A1 (en) | 2023-02-14 | 2024-08-22 | Ideaya Biosciences, Inc. | Amide and ester-substituted imidazopyridine compounds |
| US12162895B2 (en) | 2023-03-10 | 2024-12-10 | Breakpoint Therapeutics Gmbh | DNA polymerase theta inhibitor for treatment of cancer |
| WO2024209035A1 (en) | 2023-04-05 | 2024-10-10 | Forx Therapeutics Ag | Parg inhibitory compounds |
| GB202306601D0 (en) | 2023-05-04 | 2023-06-21 | Cancer Research Tech Ltd | Inhibitor compounds |
| GB202307924D0 (en) | 2023-05-26 | 2023-07-12 | Neophore Ltd | Inhibitor compounds |
| GB2631509A (en) | 2023-07-04 | 2025-01-08 | Univ Liverpool | Compositions |
| GB2631507A (en) | 2023-07-04 | 2025-01-08 | Univ Liverpool | Compositions |
| WO2025046148A1 (en) | 2023-09-01 | 2025-03-06 | Forx Therapeutics Ag | Novel parg inhibitors |
| WO2025056923A1 (en) | 2023-09-15 | 2025-03-20 | Cambridge Enterprise Limited | Combination therapy |
| WO2025073792A1 (en) | 2023-10-02 | 2025-04-10 | Forx Therapeutics Ag | Wrn inhibitory compounds |
| WO2025073870A1 (en) | 2023-10-03 | 2025-04-10 | Forx Therapeutics Ag | Parg inhibitory compound |
| GB202315149D0 (en) | 2023-10-03 | 2023-11-15 | Celleron Therapeutics Ltd | Combination therapy |
| GB202316595D0 (en) | 2023-10-30 | 2023-12-13 | Storm Therapeutics Ltd | Inhibitory compounds |
| GB202316683D0 (en) | 2023-10-31 | 2023-12-13 | Storm Therapeutics Ltd | Inhibitory compounds |
| WO2025093755A1 (en) | 2023-11-01 | 2025-05-08 | Forx Therapeutics Ag | Novel parc inhibitors |
| GB202317368D0 (en) | 2023-11-13 | 2023-12-27 | Breakpoint Therapeutics Gmbh | Novel compounds, compositions and therapeutic uses thereof |
| WO2025104443A1 (en) | 2023-11-14 | 2025-05-22 | Storm Therapeutics Ltd | Inhibitory compounds |
| WO2025114480A1 (en) | 2023-11-28 | 2025-06-05 | Forx Therapeutics Ag | Wrn inhibitory compounds |
| WO2025136811A1 (en) | 2023-12-18 | 2025-06-26 | Ideaya Biosciences, Inc. | Chemical compounds and uses thereof |
| GB202319863D0 (en) | 2023-12-21 | 2024-02-07 | Breakpoint Therapeutics Gmbh | Movel compounds, compositions and therapeutics uses thereof |
| GB202319864D0 (en) | 2023-12-21 | 2024-02-07 | Breakpoint Therapeutics Gmbh | Novel compounds, compositions and therapeutic uses thereof |
| WO2025133396A1 (en) | 2023-12-22 | 2025-06-26 | Forx Therapeutics Ag | Novel bicyclo heteroaryl parg inhibitors |
| WO2025133395A1 (en) | 2023-12-22 | 2025-06-26 | Forx Therapeutics Ag | Bicyclic (hetero)arylene wrn inhibitory compounds |
| WO2025191176A1 (en) | 2024-03-14 | 2025-09-18 | Forx Therapeutics Ag | Wrn inhibitory compounds |
| NL2037411B1 (en) | 2024-04-08 | 2025-10-31 | Univ Leiden | Protac compounds |
| GB202407738D0 (en) | 2024-05-31 | 2024-07-17 | Storm Therapeutics Ltd | Inhibitory compounds |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5538325A (en) | 1978-09-11 | 1980-03-17 | Sankyo Co Ltd | 4-anilinoquinazoline derivative and its preparation |
| IL89029A (en) | 1988-01-29 | 1993-01-31 | Lilly Co Eli | Fungicidal quinoline and cinnoline derivatives, compositions containing them, and fungicidal methods of using them |
| US5411963A (en) * | 1988-01-29 | 1995-05-02 | Dowelanco | Quinazoline derivatives |
| US5721237A (en) | 1991-05-10 | 1998-02-24 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties |
| US5710158A (en) | 1991-05-10 | 1998-01-20 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
| AU658646B2 (en) | 1991-05-10 | 1995-04-27 | Rhone-Poulenc Rorer International (Holdings) Inc. | Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
| NZ243082A (en) | 1991-06-28 | 1995-02-24 | Ici Plc | 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof |
| PT100905A (pt) * | 1991-09-30 | 1994-02-28 | Eisai Co Ltd | Compostos heterociclicos azotados biciclicos contendo aneis de benzeno, ciclo-hexano ou piridina e de pirimidina, piridina ou imidazol substituidos e composicoes farmaceuticas que os contem |
| GB9300059D0 (en) * | 1992-01-20 | 1993-03-03 | Zeneca Ltd | Quinazoline derivatives |
| GB9323290D0 (en) | 1992-12-10 | 1994-01-05 | Zeneca Ltd | Quinazoline derivatives |
| JP2890267B2 (ja) | 1994-02-23 | 1999-05-10 | ファイザー インク． | ４−ヘテロサイクリル−置換キナゾリン誘導体、その調製法および抗癌剤としてのその使用法 |
| WO1995024190A2 (en) | 1994-03-07 | 1995-09-14 | Sugen, Inc. | Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof |
| GB9510757D0 (en) | 1994-09-19 | 1995-07-19 | Wellcome Found | Therapeuticaly active compounds |
| TW321649B (enExample) | 1994-11-12 | 1997-12-01 | Zeneca Ltd | |
| GB2295387A (en) | 1994-11-23 | 1996-05-29 | Glaxo Inc | Quinazoline antagonists of alpha 1c adrenergic receptors |
| GB9424233D0 (en) * | 1994-11-30 | 1995-01-18 | Zeneca Ltd | Quinazoline derivatives |
| DE69536015D1 (de) | 1995-03-30 | 2009-12-10 | Pfizer Prod Inc | Chinazolinone Derivate |
| US6046206A (en) * | 1995-06-07 | 2000-04-04 | Cell Pathways, Inc. | Method of treating a patient having a precancerous lesions with amide quinazoline derivatives |
| GB9514265D0 (en) | 1995-07-13 | 1995-09-13 | Wellcome Found | Hetrocyclic compounds |
| GB9624482D0 (en) * | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
| US5760041A (en) | 1996-02-05 | 1998-06-02 | American Cyanamid Company | 4-aminoquinazoline EGFR Inhibitors |
| WO1997030035A1 (en) | 1996-02-13 | 1997-08-21 | Zeneca Limited | Quinazoline derivatives as vegf inhibitors |
| GB9603097D0 (en) | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline compounds |
| GB9603095D0 (en) | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
| EP0912559B1 (en) | 1996-07-13 | 2002-11-06 | Glaxo Group Limited | Fused heterocyclic compounds as protein tyrosine kinase inhibitors |
| GB9718972D0 (en) * | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
| EP0837063A1 (en) | 1996-10-17 | 1998-04-22 | Pfizer Inc. | 4-Aminoquinazoline derivatives |
| AR012634A1 (es) | 1997-05-02 | 2000-11-08 | Sugen Inc | Compuesto basado en quinazolina, composicion famaceutica que lo comprende, metodo para sintetizarlo, su uso, metodos de modulacion de la funcion deserina/treonina proteinaquinasa con dicho compuesto y metodo in vitro para identificar compuestos que modulan dicha funcion |
| TW436485B (en) | 1997-08-01 | 2001-05-28 | American Cyanamid Co | Substituted quinazoline derivatives |
| MXPA00010610A (es) * | 1998-04-29 | 2002-07-02 | Osi Pharm Inc | Mesilato de n-(e-etinilfenilamino)-6,7-bis (2-metoxietoxi)-4-quinazolinamina, anhidro y monohidratado. |
| HUP0102793A3 (en) * | 1998-05-28 | 2002-07-29 | Parker Hughes Inst St Paul | Quinazolines for treating brain tumor and medicaments containing them |
| AU4851599A (en) | 1998-06-30 | 2000-01-17 | Parker Hughes Institute | Method for inhibiting c-jun expression using jak-3 inhibitors |
| KR20010089171A (ko) | 1998-08-21 | 2001-09-29 | 추후제출 | 퀴나졸린 유도체 |
| BR9914162A (pt) | 1998-10-01 | 2001-06-26 | Astrazeneca Ab | Derivado de amida, processo para preparar um derivado de amida, ou um sal farmaceuticamente aceitável ou éster clivável in vivo do mesmo, composição farmacêutica e uso de um derivado de amida, ou um sal farmaceuticamente aceitável ou éster clivável in vivo do mesmo |
| HK1039126B (en) | 1998-10-08 | 2005-09-30 | 阿斯特拉曾尼卡有限公司 | Quinazoline derivatives |
| WO2000031048A1 (en) * | 1998-11-19 | 2000-06-02 | Warner-Lambert Company | N-[4-(3-chloro-4-fluoro-phenylamino)-7-(3-morpholin-4-yl-propoxy)-quinazolin-6-yl]-acrylamide, an irreversible inhibitor of tyrosine kinases |
| BRPI0017548B8 (pt) | 1999-02-10 | 2023-05-02 | Astrazeneca Ab | Composto |
| AU3281600A (en) | 1999-02-27 | 2000-09-21 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 4-amino-quinazoline and quinoline derivatives having an inhibitory effect on signal transsduction mediated by tyrosine kinases |
| US6080747A (en) * | 1999-03-05 | 2000-06-27 | Hughes Institute | JAK-3 inhibitors for treating allergic disorders |
| DE19911509A1 (de) | 1999-03-15 | 2000-09-21 | Boehringer Ingelheim Pharma | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
| US6411963B1 (en) * | 1999-07-09 | 2002-06-25 | Junot Systems, Inc. | External system interface method and system |
| CZ20021009A3 (cs) | 1999-09-21 | 2002-06-12 | Astrazeneca Ab | Deriváty chinazolinu, způsob jejich přípravy a jejich pouľití jako léčiv |
| GB9922173D0 (en) | 1999-09-21 | 1999-11-17 | Zeneca Ltd | Chemical compounds |
| HK1046688A1 (zh) | 1999-09-21 | 2003-01-24 | Astrazeneca Ab | 喹唑啉化合物和含有喹唑啉化合物的藥物組合物 |
| CN1240688C (zh) | 2000-04-07 | 2006-02-08 | 阿斯特拉曾尼卡有限公司 | 喹唑啉化合物 |
| WO2002016352A1 (en) | 2000-08-21 | 2002-02-28 | Astrazeneca Ab | Quinazoline derivatives |
-
2001
- 2001-01-06 UA UA2003010151A patent/UA73993C2/uk unknown
- 2001-06-01 DE DE60105295T patent/DE60105295T2/de not_active Expired - Lifetime
- 2001-06-01 NZ NZ522204A patent/NZ522204A/en not_active IP Right Cessation
- 2001-06-01 KR KR1020027016508A patent/KR100807162B1/ko not_active Expired - Fee Related
- 2001-06-01 BR BR0111335-6A patent/BR0111335A/pt not_active IP Right Cessation
- 2001-06-01 AT AT01934176T patent/ATE275145T1/de active
- 2001-06-01 ES ES01934176T patent/ES2225545T3/es not_active Expired - Lifetime
- 2001-06-01 PT PT01934176T patent/PT1292594E/pt unknown
- 2001-06-01 EP EP01934176A patent/EP1292594B1/en not_active Expired - Lifetime
- 2001-06-01 EE EEP200200673A patent/EE05481B1/xx not_active IP Right Cessation
- 2001-06-01 CA CA002407371A patent/CA2407371C/en not_active Expired - Fee Related
- 2001-06-01 US US10/275,382 patent/US7049438B2/en not_active Expired - Lifetime
- 2001-06-01 PL PL360745A patent/PL210852B1/pl unknown
- 2001-06-01 JP JP2002501890A patent/JP3774438B2/ja not_active Expired - Lifetime
- 2001-06-01 SK SK1702-2002A patent/SK286748B6/sk not_active IP Right Cessation
- 2001-06-01 WO PCT/GB2001/002424 patent/WO2001094341A1/en not_active Ceased
- 2001-06-01 CZ CZ20023961A patent/CZ301987B6/cs not_active IP Right Cessation
- 2001-06-01 HU HU0301046A patent/HU229290B1/hu not_active IP Right Cessation
- 2001-06-01 IL IL15275401A patent/IL152754A0/xx unknown
- 2001-06-01 KR KR1020087002129A patent/KR20080015055A/ko not_active Withdrawn
- 2001-06-01 MX MXPA02011765A patent/MXPA02011765A/es active IP Right Grant
- 2001-06-01 AU AU2001260482A patent/AU2001260482B2/en not_active Ceased
- 2001-06-01 CN CNB01810830XA patent/CN100345844C/zh not_active Expired - Lifetime
- 2001-06-01 SI SI200130193T patent/SI1292594T1/xx unknown
- 2001-06-01 DK DK01934176T patent/DK1292594T3/da active
- 2001-06-01 AU AU6048201A patent/AU6048201A/xx active Pending
- 2001-06-05 MY MYPI20012632 patent/MY127369A/en unknown
- 2001-06-06 AR ARP010102704A patent/AR030937A1/es active IP Right Grant
- 2001-06-06 TW TW090113714A patent/TWI288748B/zh not_active IP Right Cessation
-
2002
- 2002-11-11 IL IL152754A patent/IL152754A/en not_active IP Right Cessation
- 2002-11-28 BG BG107332A patent/BG65836B1/bg unknown
- 2002-12-02 IS IS6647A patent/IS2114B/is unknown
- 2002-12-02 NO NO20025792A patent/NO324838B1/no not_active IP Right Cessation
- 2002-12-30 CO CO02117241A patent/CO5700751A2/es active IP Right Grant
-
2005
- 2005-11-21 US US11/283,415 patent/US7696214B2/en not_active Expired - Lifetime
-
2010
- 2010-01-29 US US12/696,489 patent/US20100280042A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2003535859A5 (enExample) | ||
| JP3774438B2 (ja) | 腫瘍の処置用のキナゾリン誘導体 | |
| EP1450808B1 (en) | Quinazoline derivatives for the treatment of t cell mediated diseases | |
| KR100821446B1 (ko) | 퀴나졸린 유도체 | |
| RU2003107683A (ru) | Производные хиназолина | |
| EP1218353B1 (en) | Quinazoline derivatives | |
| JP4326328B2 (ja) | キノリン誘導体及びそれらのチロシンキナーゼ阻害薬としての使用 | |
| US20100029673A1 (en) | Therapeutic agents comprising an anti-angiogenic agent in combination with an src-inhibitor and their therapeutic use | |
| JP4307843B2 (ja) | キナゾリン誘導体 | |
| JP2004512335A (ja) | キナゾリン誘導体 | |
| JP2004511480A (ja) | キナゾリン誘導体 | |
| JP2006506463A5 (enExample) | ||
| RU2005117337A (ru) | Производные хиназолина в качестве ингибиторов src тирозинкиназы | |
| JP2006508944A5 (enExample) | ||
| US20050014773A1 (en) | Therapeutic use | |
| US7223756B2 (en) | Quinazoline compounds with therapeutic use | |
| RU2276151C2 (ru) | Хиназолиновые производные для лечения опухолей | |
| ZA200300569B (en) | Quinazoline derivatives. |